Skip to main content

Advertisement

SpringerLink
Log in

The role of inflammation in the pathogenesis of heart failure

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Heart failure is not a simple defect in the pumping function of cardiac muscle, but rather a complex systemic inflammatory disease affecting many organ systems. Recognition of this fact has led to new therapeutic interventions such as angiotensin-converting enzyme inhibitors and β-blockers, which have a significant impact on the quality of life and survival of patients with heart failure. During the course of heart failure, the steps involved in the activation of inflammation are now better understood. As a result, new therapies will develop that block, modify, or prevent these inflammatory changes, and supplement our armamentarium for providing better and longer lives for patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685–691.

    Article  Google Scholar 

  2. Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669–677.

    Article  PubMed  CAS  Google Scholar 

  3. Eichhorn EF, Bristow MR: The carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med 2001, 2:20–23.

    Article  PubMed  CAS  Google Scholar 

  4. Torre-Amione G, Kapadia S, Lee J, et al.: Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995, 92:1487–1493.

    PubMed  CAS  Google Scholar 

  5. Torre-Amione G, Kapadia S, Lee J, et al.: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93:704–711.

    PubMed  CAS  Google Scholar 

  6. Torre-Amione G, Kapadia S, Benedict C, et al.: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996, 27:1201–1206.

    Article  PubMed  CAS  Google Scholar 

  7. Bozkurt B, Torre-Amione G, Soram OZ, et al.: Results of a multidose phase I trial with tumor necrosis factor receptor (p75) fusion protein (Entanercept) in patients with heart failure. J Am Coll Cardiol 1999, 34:177–180. One of the first trials utilizing anti-TNF-a therapy in heart failure patients.

    Article  PubMed  CAS  Google Scholar 

  8. Deswal A, Bozkurt B, Seta Y, et al.: Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999, 99:3224–3226. Confirms safety of anti-TNF-α therapy in patients with heart failure.

    PubMed  CAS  Google Scholar 

  9. Louis A, Cleland JG, Crabbe S, et al.: Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001, 3:381–387. Summary and preliminary data on large-scale use of anti-TNF-a therapy.

    Article  PubMed  CAS  Google Scholar 

  10. Torre-Amione G, Stetson SJ, Youker KA, et al.: Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: a potential mechanism for cardiac recovery. Circulation 1999, 100:1189–1193. Original study in which authors demonstrate the importance of volume and pressure overload in TNF-a expression.

    PubMed  CAS  Google Scholar 

  11. Nakano M, Knowlton AA, Dibbs Z, et al.: Tumor necrosis factor-alpha confers resistance to hypoxic injury in the adult mammalian cardiac myocyte. Circulation 1998, 97:1392–1400.

    PubMed  CAS  Google Scholar 

  12. Bryant D, Becker L, Richardson J, et al.: Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor alpha. Circulation 1998, 97:1375–1381.

    PubMed  CAS  Google Scholar 

  13. Mouthon L, Kaveri SV, Spalter SH, et al.: Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996, 104(Suppl 1):3–9.

    PubMed  CAS  Google Scholar 

  14. McNamara DM, Holubkov R, Starling RC, et al.: Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001, 103:2254–2259. Pivotal trial showing no added benefit for IVIG in patients with new onset cardiomyopathy.

    PubMed  CAS  Google Scholar 

  15. Gullestad L, Aass H, Fjeld JG, et al.: Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001, 103:220–225. Small trial showing benefit for prolonged administration of IVIG in patients with new-onset cardiomyopathy.

    PubMed  CAS  Google Scholar 

  16. Muller J, Wallukat G, Dandel M, et al.: Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000, 101:385–391. Small trial showing benefit with immunoadsorption in patients with cardiomyopathy.

    PubMed  CAS  Google Scholar 

  17. Shivji GM, Suzuki H, Mandel AS, et al.: The effects of VAS972 therapy on allergic contact hypersensitivity. J Cutaneous Med Surg 2000, 4:132–137. Use of novel immunomodulating therapy in contact hypersensitivity.

    CAS  Google Scholar 

  18. Freed I, Shahid S, Wang B, et al.: Role of transforming growth factor b-1 in the Th1/Th2 mechanisms of Vasogen’s immune modulation therapy: potential role in psoriasis. J Invest Dermatol 2001, 117:388.

    Google Scholar 

  19. Packer M, Carver JR, Rodeheffer RJ, et al.: Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med 1991, 325:1468–1475.

    Article  PubMed  CAS  Google Scholar 

  20. Cohn JN, Goldstein SO, Greenberg BH, et al.: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure: Vesnarinone Trial Investigators. N Engl J Med 1998, 339:1810–1816.

    Article  PubMed  CAS  Google Scholar 

  21. Packer M, Rouleau J, Swedberg K, et al.: Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study [abstract]. Circulation 1993, 88(suppl 1):I-301.

    Google Scholar 

  22. Kubo SH, Gollub S, Bourge R, et al.: Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. Circulation 1992, 85:942–949.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Cardiology, Baylor College of Medicine, 6550 Fannin, Suite 1901, 77030, Houston, TX, USA

    Guillermo Torre-Amione MD, PhD

Authors
  1. Kevin A. Lisman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sonny J. Stetson BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael M. Koerner MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John A. Farmer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guillermo Torre-Amione MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lisman, K.A., Stetson, S.J., Koerner, M.M. et al. The role of inflammation in the pathogenesis of heart failure. Curr Cardiol Rep 4, 200–205 (2002). https://doi.org/10.1007/s11886-002-0051-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-002-0051-3

Keywords

Search

Navigation